Skip to main content
Premium Trial:

Request an Annual Quote

NuSep to Buy BioInquire

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian bioseparations company NuSep has signed an agreement to buy proteomics software maker BioInquire through a cash, stock, and milestone arrangement worth an expected $3 million or more.

BioInquire, based in Athens, Ga., sells the ProteoIQ software for analysis and identification of protein samples post-processing on a mass spec instrument against large structure and function databases.

NuSep said that its customers can use the ProteoIQ software to identify proteins they separated with its ProteomeSep MF10 instruments.

NuSep offers precast gels, separation instruments, including the ProteomeSep, biological research supplies, and the InqSep supply service for identification, cataloguing, and analysis for mass spectrometry projects.

Under the agreement, NuSep will pay three times BioInquire's 2010 calendar net profit. That includes $1.5 million when the acquisition is approved; $500,000 in NuSep shares at the end of 2010; $1 million on March 31, 2011, based on achievement of a profit milestone; and the balance of three times the BioInquire net profit for the 12 months up to March 2011.

NuSep expects the combined company to have $5.5 million in revenues for the 09/10 Fiscal Year ended June 30, 2010.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more